Borrelia burgdorferi and Demyelinating Disease: A Convergence Hypothesis with Adjuvant-Aluminum Monocytic Trafficking

Background Borrelia burgdorferi is the spirochete of Lyme disease. In most neuroborreliosis cases the route into the nervous system is focal/perineural-radicular (facial palsy, Bannwarth radiculitis), but a minority subgroup, estimated at 0.3-1% of neuroborreliosis, follows a documented cerebral-vasculitis route, with a clinical and radiological phenotype that can mimic multiple sclerosis (MS). LYMErix, an aluminum-hydroxide-adjuvanted OspA vaccine withdrawn from the market in 2002, was followed by post-marketing reports of demyelinating and cerebrovascular neurological events, in contrast with ImuLyme, the same antigen formulated without adjuvant. Hypothesis We propose that, in the vascular subgroup of neuroborreliosis, aluminum-laden CCR2+ monocytes generated at a vaccination site are recruited toward the compartment Borrelia has already compromised, following a CCL2 gradient — the same cellular second-hit mechanism proposed for Bartonella henselae in this series, here tested against a pathogen whose dominant (perineural) route is independently rated by the general framework as poorly matched to that mechanism. Borrelia is the only one of the framework's pathogens for which documented human vaccine coexposure data (LYMErix) exist, even though those data remain phenotypic rather than mechanistic. Conclusions The scenario places direct causal weight on the topology of the vascular lesion itself, and reduces the vaccine to a transportable cellular aluminum source contingent on that lesion remaining permeable, perfused, and sufficiently long-lived. Two OspA-derived sequence-mimicry hypotheses examined here each fail the same criterion of Oldstone's four-part test, reinforcing this series' general argument against classical molecular mimicry as a discriminating mechanism.